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Introduction 
Abortion is defined as the termination of  pregnancy by the re-
moval or expulsion from the uterus of  a fetus or embryo prior to 
viability. An abortion can occur spontaneously, in which case it is 
usually called a miscarriage, or it can be purposely induced. The 
term abortion most commonly refers to the induced abortion of  a 
human pregnancy.
Medical abortion besides being private, convenient and less in-
vasive has been found to alleviate the complication of  surgically 
performed abortion. For termination of  early pregnancy, the effi-
cacy and tolerability of  mifepristone in combination with vaginal 
misoprostol have already been established. 
The Indian abortion laws fall under the Medical Termination of  
Pregnancy (MTP) Act, which was enacted by the Indian Parlia-
ment in the year 1971. The MTP Act came into effect from April 
1, 1972 and was once amended in 1975.
The Medical Termination of  Pregnancy (MTP) Act of  India clear-
ly states the conditions under which a pregnancy can be ended or 
aborted, the persons who are qualified to conduct the abortion 
and the place of  implementation.
Mifepristone is a synthetic steroid compound used as a pharma-
ceutical. It is a progesterone receptor antagonist used as an abor-
tifacient in the first months of  pregnancy, and in smaller doses as 
an emergency contraceptive.
Abstract
Medical abortion has been investigated as a non-invasive option for early abortions as it avoids the risk of  anesthesia and surgical trauma 
to the cervix, uterus and other organs.
The main aim of  the study was to compare the efficacy and safety of  abortion using the drugs mifepristone and vaginal misprostol V/s 
misoprostol alone.
A randomized control study was done in 100 women who came for termination of  pregnancy up to 63 days in family planning unit at 
Government Medical College Hospital, Kottayam, India for one year period.
The mean age of  the study group was 25.4 years of  age. Complete abortion occurred in 94% with Mifepristone and Misiopristol regime 
(Group A) and 86% of  Misoprostol alone regimn(Goup B). There was a 100% complete abortion rate with mifepristone  and misopros-
tol in POGs up to 49 days. Complete abortion showed better compliance with Misoprolstol alone regimn in Primigravida (100%) and, 
Mefepristone and Misoprostol  regime with multigravida (97%). The mean period of  bleeding was 5.7 in Group A and 7.6 in Group B.
Mifepristone and Misiopristol regime showed better outcome than Misoprostol alone for medical termination of  pregnancy till first 9 
weeks of  gestation
Keywords: Mifepristone, Misiopristol, Medical termination of  pregnancy
Abbreviations:
MTP  -Medical Termination of Pregnancy
IUD   -Intra Uterine Device 
MVA  - Manual Vacuum Aspiration
EVA   - Electric Vacuum Aspiration
D&E  - Dilatation and Evacuation
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Misoprostol, a prostaglandin, binds to myometrial cells to cause 
strong myometrial contractions leading to expulsion of  tissue. 
Misoprostol is commonly used for labor induction. It causes uter-
ine contractions and the ripening (effacement or thinning) of  the 
cervix.
Oral mifepristone (Ru 486) in doses of  200-600 μg has been suc-
cessfully used in pregnancy termination up to 63 days, in combi-
nation with misoprostol administered orally in doses of  400 – 800 
μg or vaginally either simultaneously or increasing dosing inter-
vals. Antiprogestin Ru 486 discovered in France is widely popular 
in the country of  its origin where it is used in association with 
orally administered mifepristone, unlike the vaginally inserted that 
is favour in other centers. 
The combination of  mifepristone is acceptable in various Euro-
pean nations such as the UK, USA or any other affluent nation 
where the high cost of  mifepristone is not a big problem. Where 
as for women living in developing countries, misprostol, a pros-
taglandin E1 analogue like gemeprost, became more acceptable 
as it is cheaper and can potentially induce uterine contractions, 
thereby facilitating abortion with a successful rate of  above 85%. 
Misoprostol has been combined with methotrexate (both oral and 
intramuscular) with similar results or with tamoxifen which has 
given mixed results.
In this respect, I tried to adopt a World Health Organization – 
developed, effective, evidence-based regimen (developed in 2003) 
for early trimester pregnancy termination, consisting of  200 mg 
mifepristone given orally followed 24 hrs by vaginal misoprostol 
400 μg 4th hourly to a maximum of  five doses which has been 
found to be more effective than same dose of  misoprostol alone 
used vaginally.
My aim was to explore whether the combination of  mifepristone 
and misoprostol could bring an improvement in the complete 
abortion rate in women, which was 85% with the use of  vaginal 
misoprostol alone and to compare the side effects.
Objectives
1. To determine the clinical advantage of  pre treatment with Mife-
pristone in early pregnancy termination
2. To compare the efficacy of  a combination of  Mifepristone with 
vaginal Misoprostol with vaginal Misoprostol alone for medical 
abortion.
3. To compare the side effects between the combination of  Mife-
pristone with vaginal Misoprostol with vaginal Misoprostol alone 
for medical abortion.
Material and Methods
Study design: Hospital based Randomized Controlled Trial 
Study setting: Family Planning unit at tertiary care teaching hos-
pital, Government Medical College Hospital, Kottayam.
Case definition: Women who came for termination of  preg-
nancy up to 63 days to the family planning unit at Government 
Medical College Hospital, Kottayam over the period of  one year 
ranging from may 2011 to May, 2012 and were selected at random 
for the study.
Inclusion Criteria
• Women who need termination of  pregnancy due to various  
reasons. 
•  Primigravida or women with history of  normal labour.
•  TVS demonstrating a live intra uterine pregnancy up to 63 days 
gestation with visibility of  fetal pole or mass with cardiac activity.
•  Estimated Hb level 10 gm% or more.
Exclusion Criteria
• Blighted ovum
• Incomplete or missed abortion
• IUCD co-existing with pregnancy




• H/o allergy to drugs in trial
Sampling
Patients in the Family Planning OP, Government Medical College 
Hospital, Kottayam, India.
Study Method
Women requesting termination of  pregnancy within 9 weeks 
from the onset of  amenorrhea will be recruited for the study. 
Women who enrolled will be given written informed consent and 
agreed to have suction evacuation should the pregnancy be viable 
at the follow-up visit or anytime if  heavy bleeding occurs. 
The gestational age will be confirmed in all women by Trans vagi-
nal scan examination. Randomized cards based on computer gen-
erated random numbers will be stocked in FP unit and patients 
are allocated accordingly. The patients who receive Mifepristone 
Misoprostol combination trial are given Mifepristone 200 mg oral 
from OP and advised to come on next day. Patient in both trial 
group are admitted in hospital for proper observation on the day 
of  Misoprostol trial. If  the patient’s blood type is Rh negative, she 
will be given Inj anti D intramuscularly. Patients in both groups 
will be given Misoprostol 400 mcg 4th hrly up to a 5 maximum 
doses. Patient’s vitals will be monitored soon after the administra-
tion of  vaginal misoprostol and then at 3rd hr for each dose. The 
patients are kept under observation until they undergo complete 
abortion or till the end of  the 5th dose which ever is earlier. At the 
end of  the 5th dose the patients are allowed to go home. 
Patients will be asked to record the onset of  bleeding, timing of  
passage of  products of  conception, duration of  bleeding, and 
side effects for the next 14 days. They will also be instructed to 
come to hospital in case of  heavy bleeding (soaking of  more than 
2 pads per hour for more than 2 hrs or severe pain or any other 
complication. They will be asked to come for a follow-up visit on 
day 15 when vaginal examination and pelvic ultrasound examina-
tion will be carried out. For each woman, the outcome will be 
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In complete abortion the uterine cavity will be empty and the 
endometrial thickness will be less than 15 mm through the TVS. 
In incomplete abortion there may be retained products of  con-
ception and endometrial thickness will be less than 15 mm. In 
missed abortion the gestational sac may be present but without 
any cardiac activity in embryo. In continuation of  pregnancy the 
live fetus is present in the gestational sac. Women with treatment 
outcomes in the last three categories will be further managed by 
suction evacuation of  the uterus. Success will be defined as com-
plete expulsion of  the products of  conception with no need for 
surgical intervention.
The induction abortion interval is defined as the time interval 
from administration of  Mifepristone in Mifepristone Misoprostol 
combination trial group and from administration of  misoprostol 
in misoprostol only group to the passage of  products of  concep-
tion 
Analysis
Maternal details were entered in the computer [Excel data sheet] 
and analyzed using SPSS 11.
Discussion
From this study of  medical abortion in <63 days ‘ gestation, the 
success rate of  complete abortion with mifepristone 200 mcg fol-
lowed by vaginal misoprostol was 94%, compared to success rate 
of  86% for vaginal misoprostol used alone in repeated doses. Sur-
gical evacuation was needed in 10 cases; seven for cases of  incom-
plete abortion -three in group a (6%) and four in group B (8%) 
and the other three evacuations were performed for pregnancy 
continuation in group B (6%)
In total more favourable outcome were observerd with the com-
bination of  mifepristone and misprostol giving a complete abor-
tion rate that is equal to or slightly less then other studies carried 
out in pregnancy of≤ 63 days. Almost all of  these studies achiev-
ing success rates of  95% have invariably incorporated a large 
number of  subject ranging from 800-1200. 2,4,5-7,14,18 One 
such study ‘ Low dose mifepristone 200 mcg and vaginal mis-
oprostol for abortion’ conducted by Schaff  E.A ,Essenger S.H, 
and Stadalius L.S at Dept of  family medicine , Rochester Univer-
sity of  Medicine ,Newyork in 933 women showed complete abor-
tion rate of  97%. Nevertheless, there are some studies that have 
been tried in small number of  women 12,17,19,23 Another study 
‘Mifepristone plus vaginal misoprostol vs vaginal misoprostol 
alone for medical abortion in first trimester conducted by Rashmi 
Chawdhary,Ashma Rana and Neelam Pradhan in Thribhuvan 
University , Kathmandu among 194 women showed a complete 
abortion rate of  95% in the combination group.
A large multi centric Cochrane data base analysis conducted by 
WHO on Medical methods of  first trimester abortion reviewed 58 
trials out of  which 5 trials compared the efficacy of  prostaglandin 
alone to combination regimen of  prostaglandin and mifepristone. 
All these trials showed higher effectiveness with combination trial. 
Regarding gravidity, with the exception of  two incomplete abor-
tions which occurred in group A, the rest of  the Primigravida 
(90.4%) aborted completely. This was almost equal to the com-
plete abortion rate in multigravida (89.8%). Incomplete abortion 
(9.5%) in Primigravida, however was more frequent than multi-
gravida (6.3%) but without any significant differences, while preg-
nancy continuation occurred only in multigravida (3.8%) and all 
of  them belong to Group B. In group B, pregnancy continuation 
(three) and incomplete abortion (four) occurred in multigravida 
(seven). In group A, incomplete were seen more in Primigravida 
(two) than multigravida(one).
Gestational age is one of  the parameters for the success of  the 
medical abortion. Medical abortion with misoprostol failed in 
three women in group B when their gestational age in days was 
<56 days (35,36,53 days ). Further, in the case of  incomplete 
abortion, the gestational age was 51,62 and 63 days (Group A) 
or 39,56 and 63 days (Group B). Yet the mifepristone and mis-
oprostol regime resulted in a 100% complete abortion rate when 
the duration of  amenorrhea was <49 days. This is an impressive 
finding compared to the research conducted for confirming the 
safety and efficacy in pregnancy < 49 days which gave success 
rate below 100% 19,21. Efficacy, however decreased significantly 
when the duration of  pregnancy was more than 49-63 days of  
amenorrhea.
  
A study worth mentioning is ‘ Misoprostol for abortion up to 9 
wks gestation in adolescents’ by Velazco A, Valera L et al com-
pared 800μg vaginal misoprostol in its normal form without wet-
ting or using the water- wet form inserted on days 1, 3 and 5 
resulting in a complete abortion rate of  85% Further, the suc-
cess rate was stretched up to 88% in 150 adolescents with a simi-
lar dosing interval and dosage of  vaginal misoprostol in normal 
forms. However the success rate of  vaginal misopristol alone was 
only 85-88% in comparison to its combination with mifepristone, 
which gave a success rate of  above 92%. On the basic of  the 
lower success rate, there are contradicting views as to whether it is 
appropriate or not to use misoprostol for pregnancy termination.
Misoprostol is usually associated with more side effects such as 
nausea vomiting, diarrhea, fever and shivering, and with the ex-
ception of  one study , mifepristone has appeared to have fewer 
side effect 5,14,15,22,23. One of  the main disadvantages that 
could reduce the acceptability of  medical abortion is its longer 
duration of  bleeding, which was also observational finding in this 
study.
The percentage of  complete abortion after first dose of  mis-
oprostole in group A was 23% and after each subsequent dose 
of  the drug was 59%,86%,92% and 94%, while in group B it was 
18%,42%,69%,83%,86%.
One the whole, this experimental study has shown safety, toler-
ability and a better success rate when the combination regime of  
oral mifepristone and vaginal misoprostol is used, congruous to 
other study findings 4,5,14,. Probably success rate could have im-
proved had we implicated the insertion used a different dosing 
interval schedule of  4-8 or 5 days. 
There are a number of  limitations that should be noted, as this 
preliminary study with a small sample size was not really big 
enough to measure differences. Even with a complete abortion 
judged by ultrasound in six cases, the second treatment with mis-
oprostol repeated on day 3 could have reduced the duration and 
amount of  bleeding. Efficacy rates could have been improved 
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with a longer window period than just 24hrs. 
Observations
A total of  100 women were included in the study group which 
comprises 50 women from Mifepristone + Misoprostol [GROUP 
A] and 50 women from Misoprostol alone [GROUP B] after sat-
isfying the inclusion and exclusion criteria. Various findings of  the 
Table 1: Distribution of  study population according to their age
AGE 
 (Years)
No. OF PATIENTS TOTAL
GROUP  A GROUP  B
18-24 17(34%) 21 (42%) 38
25-30 20 (40%) 16 (32%) 36
31-36 11 (22%) 9 (18%) 20
37-42 2 (4%) 4 (8%) 6

















   Figure 1
Majority of  women in Group A were in the age group 25-30 and in Group B were between 18-24. The mean maternal age in Group A 
was 26.1 and Group B was 24.7
Table 2. Distribution showing the outcome of  the study on day 15
ABORTION GROUP A GROUP B P- VALUES
Complete 47(94%) 43(86%) 0.317
Incomplete 3(6%) 4(8%) 1.O
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Following up on day 15 showed complete abortion had occurred in 90 women (47 in group A[94%] and 43 in group B [86%]). Incom-





Complete Incomplete Continuation of pregnancy
Table 3. Distribution of  study group in relation to complete abortion with their gestational age
GESTATIONAL AGE IN DAYS GROUP A GROUP B P-VALUES
n Complete abortion n Complete abortion
< / = 35 9 9(100%) 8 7(87.5%) 0.471
36 – 42 8 8(100%) 9 6(66.7%) 0.21
43 – 49 16 16(100%) 11 11(100%) 0
50 – 56 7 6(85.7%) 12 10(83.3%) 1.O
57 – 63 10 88(80%) 10 9(90%) 1.O








< / = 35 36 - 42 43 - 49 50 - 56 57 - 63
Gestational Age (Days)




There was a 100% complete abortion rate with mifepristone  and misoprostol in POGs up to 49 days. Vaginal misoprostol alone was seen 
to give inconsistent results, although a100% complete abortion rate was seen in pregnancy with a POG of  43-49 days.
Table 4. Distribution showing final outcome of  medical abortion as per gravidity
GRAVIDA OUTCOME GROUP A GROUP B P - VALUES
Primi (n=21) Complete abortion 10 9 0.486
Incomplete abortion 2 0 0.486
Pregnancy continued 0 0 0
Multi (n=79) Complete abortion 37 34 0.058
Incomplete abortion 1 4 0.361
Pregnancy continued 0 3 0.241
TOTAL 50 50
Out of  the 21 Primigravida, complete abortions occurred in 19 while 2 pregnancies in Group A results in incomplete abortions. Of  the 
79 multigravida complete abortions occurred in 71, incomplete abortions occurred in 5 women, one pregnancy in Group A and four in 
Group B, and pregnancy continuation occurred in three women (all in group B).
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Table 5. Distribution showing side effects and complications
SIDE EFFECTS &
COMPLICATIONS
GROUP A ( n= 50 ) GROUP B ( n= 50 ) P – VALUES
Vomiting / Nausea 23 (46%) 10 (20%) 0.006
Fever >38 Celsius  - 7 (14%) 0.012
Headache 5 (10%) 11 (22%) 0.102
Shivering  - 3 (6%) 0.242
Diarrhea 2 (4%) 2 (4%) 1.O













Vomiting Fever Headache Shivering Diarrhea Analgesic
use




Side effects such as nausea and vomiting were seen more with mifepristone and misopristone (group A), while fever, headaches and 
shivering were twice in misoprotosol group .















s A, ( n= 50 )
B, ( n= 50 )
Figure 5. Graph showing the duration of  bleeding
The maximum and minimum number of  days of  bleeding was Group A was 12 and 4, and  that of  Group B was 3 and 19. The mean 
period of  bleeding was 5.7 in Group A and 7.6 in Group B.
study are presented and tabulated as follows .
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